PROCEPT BioRobotics Corporation (PRCT)

Market Cap	2.26B
Revenue (ttm)	274.95M
Net Income (ttm)	-84.15M
Shares Out	55.64M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,753
Open	40.84
Previous Close	40.80
Day's Range	40.50 - 41.14
52-Week Range	37.12 - 103.81
Beta	1.04
Analysts	Buy
Price Target	75.57 (+86.27%)
Earnings Date	Oct 27, 2025

About PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign p...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 15, 2021
• Employees: 756
• Stock Exchange: NASDAQ
• Ticker Symbol: PRCT
• Website: https://www.procept-biorobotics.com

Financial Performance

In 2024, PROCEPT BioRobotics's revenue was $224.50 million, an increase of 64.84% compared to the previous year's $136.19 million. Losses were -$91.41 million, -13.68% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for PRCT stock is "Buy." The 12-month stock price target is $75.57, which is an increase of 86.27% from the latest price.

Price Target

$75.57

(86.27% upside)

Analyst Consensus: Buy